G. Bianchi

发表

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

P. Fasching, P. Neven, F. Esteva, 2020, Breast.

292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

F. Puglisi, M. Benelli, G. Arpino, 2021, Annals of Oncology.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

P. Fasching, P. Neven, F. Esteva, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

P. Fasching, P. Neven, C. Wang, 2022, Annals of Oncology.

Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

P. Fasching, P. Neven, D. Slamon, 2021, Journal of Clinical Oncology.

LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

J. O’Shaughnessy, N. Turner, S. Ladoire, 2021, Annals of Oncology.

Abstract PD2-05: Biomarker analysis by baseline circulating tumor DNA alterations in the MONALEESA-3 study

P. Neven, S. Chia, G. Jerusalem, 2019, Poster Discussion Abstracts.

Commentaries on Data Published by Riggio et al. and Discussion by Otterburn on Locoregional Risk Following Mastectomy After Lipofilling

G. Bianchi, E. Riggio, 2014, Aesthetic Plastic Surgery.

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

P. Neven, F. Esteva, X. Pivot, 2019, Annals of Oncology.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

P. Fasching, P. Neven, F. Esteva, 2019, The New England journal of medicine.

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven, C. Wang, G. Jerusalem, 2023, Breast Cancer Research.

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.

F. Puglisi, M. Benelli, G. Arpino, 2023, European journal of cancer.